Another startup, another planet: Alderaan closes $21M A round for anti-CD25 antibodies Jan. 9, 2020 By Cormac Sheridan Alderaan Biotechnology SAS is the latest contender to enter the hotly contested world of regulatory T-cell (Treg) depletion in cancer. Read More
